Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-(L)1 inhibitors with concurrent irradiation at varied tumour sites in advanced non-small cell lung cancer
2017-005142-29Phase 3Active
- Sponsor
- Unicancer
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, nivolumab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Unicancer. Started Aug 2018; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-005142-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005142-29.